XIAP and lymphoma: Knockdown of USP9X leads to suppressed lymphoma growth and increased sensitivity to chemotherapy by destabilizing X-linked inhibitor of apoptosis protein (XIAP) in B-cell lymphoma, independently of Mcl-1 [190].